More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

The FDA approved a new indication for use for Wegovy earlier this year (REUTERS/Victoria Klesty ... Both drugs are different versions of the diabetes treatments Mounjaro and Ozempic, which are ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial ...

Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha ...